CY1118124T1 - Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας - Google Patents
Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειαςInfo
- Publication number
- CY1118124T1 CY1118124T1 CY20161100970T CY161100970T CY1118124T1 CY 1118124 T1 CY1118124 T1 CY 1118124T1 CY 20161100970 T CY20161100970 T CY 20161100970T CY 161100970 T CY161100970 T CY 161100970T CY 1118124 T1 CY1118124 T1 CY 1118124T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cells
- cell
- selected antigen
- ligand
- recognition domain
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000009469 supplementation Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 3
- 210000003289 regulatory T cell Anatomy 0.000 abstract 3
- 230000004068 intracellular signaling Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Ένα ανακατευθυνόμενο κύτταρο Treg διαθέτει ειδικότητα σε σχέση με ένα επιλεγμένο αντιγόνο ή συνδέτη-στόχο. Το κύτταρο περιέχει ένα χιμαιρικό πολυπεπτίδιο υποδοχέα, που εκφράζεται σε μια μονή, συνεχή αλυσίδα με μια εξωκυτταρική περιοχή αναγνώρισης που εμφανίζεται στην κυτταρική επιφάνεια, μια διαμεμβρανική περιοχή και μια ενδοκυτταρική περιοχή σηματοδότησης. Η εξωκυτταρική περιοχή αναγνώρισης είναι ειδική για το επιλεγμένο αντιγόνο ή συνδέτη. Η ενδοκυτταρική περιοχή σηματοδότησης περιλαμβάνει ένα συνδυασμό από ομάδες πολυπεπτιδίων που σηματοδοτούν Τ-κύτταρα, όπου ο συνδυασμός κατά την πρόσδεση της εξωκυτταρικής περιοχής αναγνώρισης στο επιλεγμένο αντιγόνο ή συνδέτη, εκκινεί την ενεργοποίηση των ανακατευθυνόμενων Treg κυττάρων για να προκαλέσουν καταστολή της ανοσίας που προκαλείται από τα Τ-κύτταρα. Τέτοιου είδους ανακατευθυνόμενα κύτταρα Treg μπορούν να χρησιμοποιηθούν στην καταστολή της ανεπιθύμητης ενέργειας των δραστικών Τ-κυττάρων προκαλώντας μια ανοσολογική ή φλεγμονώδη απόκριση. Είναι ιδιαιτέρως χρήσιμα στη θεραπεία των ασθενειών που προκαλούνται από τα δραστικά Τ-κύτταρα, όπως η φλεγμονώδης νόσος του εντέρου, η απόρριψη μοσχεύματος και η νόσο GVH.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89840807P | 2007-01-31 | 2007-01-31 | |
US95105207P | 2007-07-20 | 2007-07-20 | |
PCT/US2008/052724 WO2008095141A2 (en) | 2007-01-31 | 2008-01-31 | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118124T1 true CY1118124T1 (el) | 2017-06-28 |
Family
ID=39674803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100970T CY1118124T1 (el) | 2007-01-31 | 2016-09-29 | Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας |
Country Status (13)
Country | Link |
---|---|
US (2) | US20100135974A1 (el) |
EP (2) | EP3097923B1 (el) |
CY (1) | CY1118124T1 (el) |
DK (1) | DK2126054T3 (el) |
ES (2) | ES2595307T3 (el) |
HR (1) | HRP20161191T1 (el) |
HU (1) | HUE030386T2 (el) |
IL (1) | IL200104A0 (el) |
LT (1) | LT2126054T (el) |
PL (1) | PL2126054T3 (el) |
PT (1) | PT2126054T (el) |
SI (1) | SI2126054T1 (el) |
WO (1) | WO2008095141A2 (el) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11278594B2 (en) | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
SI2126054T1 (sl) | 2007-01-31 | 2016-12-30 | Yeda Research And Development Company Limited | Preusmerjanje, genetsko spremenjene T regulatorne celice in njih uporaba v zatiranju avtoimunske in vnetne bolezni |
WO2008097926A2 (en) | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
US20150064206A1 (en) * | 2008-04-28 | 2015-03-05 | Txcell | Compositions for treating uveitis |
ES2961498T3 (es) * | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
EP2483301A1 (en) * | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US20120244145A1 (en) * | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
EP2555753B1 (en) | 2010-04-07 | 2018-08-01 | California Institute of Technology | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
WO2011140170A1 (en) * | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
WO2011146910A1 (en) * | 2010-05-20 | 2011-11-24 | Round June L | Antigen specific tregs and related compositions, methods and systems |
WO2012131419A1 (en) * | 2011-03-25 | 2012-10-04 | Txcell | Method for using regulatory t cells in therapy |
EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
WO2013076268A1 (en) * | 2011-11-23 | 2013-05-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
WO2013169691A1 (en) | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
US10786532B2 (en) | 2012-10-02 | 2020-09-29 | Versiti Blood Research Institute Foundation, Inc. | Method of providing cellular therapy using modified natural killer cells or T lymphocytes |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
NZ712693A (en) * | 2013-03-15 | 2021-07-30 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
CA2907397C (en) | 2013-03-15 | 2022-11-22 | Anthrogenesis Corporation | Modified t lymphocytes |
EP3001836B1 (en) * | 2013-05-10 | 2019-08-07 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Design and use of specific regulatory t-cells to induce immune tolerance |
EP2994161B1 (en) | 2013-05-10 | 2020-10-28 | California Institute of Technology | Probiotic prevention and treatment of colon cancer |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
US10092597B2 (en) | 2014-01-14 | 2018-10-09 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice |
WO2016044811A1 (en) | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
CN107708811B (zh) | 2015-04-21 | 2021-04-30 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化psa組成物および方法 |
MX2018002849A (es) * | 2015-09-07 | 2018-09-05 | Inst Nat Sante Rech Med | Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos. |
WO2017058752A1 (en) | 2015-09-28 | 2017-04-06 | Trustees Of Dartmouth College | Chimeric antigen receptor anti-inflammatory cells and methods of use |
US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
US11648268B2 (en) * | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
EP3263595A1 (en) | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
JP2019528699A (ja) | 2016-08-30 | 2019-10-17 | メモリアル スローン ケタリング キャンサー センター | ウイルスおよびその他の感染を処置するための免疫細胞組成物および使用の方法 |
US11331380B2 (en) | 2016-10-20 | 2022-05-17 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
JP7069152B2 (ja) | 2016-10-31 | 2022-05-17 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 遺伝子組換えにより内在性foxp3遺伝子の発現が安定化されたcd4 t細胞を使用した自己免疫疾患の治療方法 |
WO2018127585A1 (en) * | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
EP3533451B1 (en) | 2017-01-21 | 2022-07-27 | Guangzhou Hanfang Pharmaceuticals Co., Ltd. | Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome |
US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
EP3662055A1 (en) | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
US20200215112A1 (en) * | 2017-08-09 | 2020-07-09 | Ctg Pharma Ltd. | Chimeric antigen receptor for her2/neu and t-cells expressing same |
AU2018385706A1 (en) * | 2017-12-15 | 2020-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting T cell exhaustion |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
US20200399354A1 (en) * | 2018-02-09 | 2020-12-24 | The Trustees Of Dartmouth College | Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders |
SG11202010454PA (en) * | 2018-03-23 | 2020-11-27 | Gavish Galilee Bio Appl Ltd | Genetically reprogrammed tregs expressing membrane-bound il-10 |
AU2019250692A1 (en) * | 2018-04-13 | 2020-11-05 | Sangamo Therapeutics France | Chimeric antigen receptor specific for Interleukin-23 receptor |
GB2611707A (en) * | 2018-04-18 | 2023-04-12 | Ucl Business Ltd | Method |
AU2019261438A1 (en) | 2018-04-27 | 2020-09-10 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of FOXP3 in edited CD34+ cells |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
US20210292389A1 (en) | 2018-08-10 | 2021-09-23 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
CN109975537B (zh) * | 2019-04-09 | 2022-05-24 | 上海药明生物技术有限公司 | 一种检测tim-3抗体活性的试剂盒和方法 |
CN110283827B (zh) * | 2019-07-17 | 2021-06-08 | 山东农业大学 | 松材线虫mog-2基因及其在发育干扰中应用 |
GB201915384D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Vector |
WO2022165419A1 (en) * | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040115217A1 (en) * | 1987-06-24 | 2004-06-17 | Autolmmune Inc. | Bystander suppression of autoimmune diseases |
US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
WO1993019163A1 (en) | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
US8211422B2 (en) * | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
US20030157057A1 (en) * | 1999-05-05 | 2003-08-21 | Horwitz David A. | Methods for the induction of professional and cytokine-producing regulatory T cells |
IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
WO2002072796A2 (en) | 2001-03-12 | 2002-09-19 | Cellcure Aps | Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity |
US20030015057A1 (en) | 2001-07-23 | 2003-01-23 | Spx Corporation | Extensible jack handle |
DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
US20050186207A1 (en) * | 2004-01-08 | 2005-08-25 | The Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
SI2126054T1 (sl) | 2007-01-31 | 2016-12-30 | Yeda Research And Development Company Limited | Preusmerjanje, genetsko spremenjene T regulatorne celice in njih uporaba v zatiranju avtoimunske in vnetne bolezni |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
-
2008
- 2008-01-31 SI SI200831673A patent/SI2126054T1/sl unknown
- 2008-01-31 DK DK08728776.9T patent/DK2126054T3/en active
- 2008-01-31 US US12/525,270 patent/US20100135974A1/en not_active Abandoned
- 2008-01-31 EP EP16177278.5A patent/EP3097923B1/en active Active
- 2008-01-31 ES ES08728776.9T patent/ES2595307T3/es active Active
- 2008-01-31 EP EP08728776.9A patent/EP2126054B1/en not_active Revoked
- 2008-01-31 ES ES16177278T patent/ES2926805T3/es active Active
- 2008-01-31 PL PL08728776T patent/PL2126054T3/pl unknown
- 2008-01-31 LT LTEP08728776.9T patent/LT2126054T/lt unknown
- 2008-01-31 WO PCT/US2008/052724 patent/WO2008095141A2/en active Application Filing
- 2008-01-31 PT PT87287769T patent/PT2126054T/pt unknown
- 2008-01-31 HU HUE08728776A patent/HUE030386T2/en unknown
-
2009
- 2009-07-28 IL IL200104A patent/IL200104A0/en unknown
-
2016
- 2016-09-19 HR HRP20161191TT patent/HRP20161191T1/hr unknown
- 2016-09-29 CY CY20161100970T patent/CY1118124T1/el unknown
-
2019
- 2019-03-22 US US16/361,852 patent/US11326147B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK2126054T3 (en) | 2016-10-03 |
LT2126054T (lt) | 2016-10-10 |
PT2126054T (pt) | 2016-10-12 |
HUE030386T2 (en) | 2017-05-29 |
PL2126054T3 (pl) | 2017-01-31 |
SI2126054T1 (sl) | 2016-12-30 |
HRP20161191T1 (hr) | 2016-11-18 |
WO2008095141A2 (en) | 2008-08-07 |
EP3097923B1 (en) | 2022-07-27 |
US20100135974A1 (en) | 2010-06-03 |
US11326147B2 (en) | 2022-05-10 |
IL200104A0 (en) | 2010-04-15 |
ES2926805T3 (es) | 2022-10-28 |
EP3097923A1 (en) | 2016-11-30 |
EP2126054B1 (en) | 2016-07-06 |
ES2595307T3 (es) | 2016-12-29 |
WO2008095141A3 (en) | 2008-12-11 |
EP2126054A2 (en) | 2009-12-02 |
US20200056152A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118124T1 (el) | Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας | |
CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
CY1120707T1 (el) | Anti-cd28 εξανθρωπισμενα αντισωματα | |
CY1122210T1 (el) | Ανθρωπινα αντισωματα anti-sod1 | |
CY1119760T1 (el) | Χρηση τ κυτταρων τροποποιημενων απο χιμαιρικο υποδοχεα αντιγονου για τη θεραπευτικη αγωγη καρκινου | |
CY1118072T1 (el) | Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων | |
CY1122435T1 (el) | Ποντικοι με εξανθρωπισμενη καθολικη ελαφρια αλυσιδα | |
EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
DOP2023000165A (es) | Anticuerpos de unión a cd3 | |
CY1121558T1 (el) | Διλειτουργικα πολυπεπτιδια | |
CO2018013471A2 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
MD3652215T2 (ro) | Moleculă polipeptidică îmbunătăţită cu specificitate duală | |
CY1119696T1 (el) | Cc-1065 αναλογα και τα συζευγματα αυτων | |
MX2023002653A (es) | Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos. | |
CY1126121T1 (el) | Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων | |
PE20121616A1 (es) | Anticuerpos anti-her3 | |
NZ743310A (en) | Method and compositions for cellular immunotherapy | |
BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
CY1120055T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
SG10201805411YA (en) | Chimeric antigen receptors | |
MX347515B (es) | Agentes que se unen al receptor encrespado y usos de los mismos. | |
IN2014MN01879A (el) |